With 2 mL bacteriostatic water
10.0 units
Page last checked
Reconstitution · KPV
Pick the vial, the water you added and the dose. Get the exact draw in units for the syringe in your hand.
Step 1 of 4
This vial holds 10,000 mcg in total.
U-100 insulin syringe · 1 mL · lines every 2 units · 1 unit = 0.01 mL
15.0 units on a U-100 insulin syringe · 1 mL · lines every 2 units, which is 0.15 milliliters. The nearest syringe line is 16 units.
Your address is used to send this one card. The email also includes an optional link for updates when our data changes. Nothing else is sent unless you choose that link, and you can unsubscribe anytime.
KPV is three amino acids — lysine, proline, valine. They are the tail end of the hormone that controls skin pigment. It is sold for gut inflammation, and for eczema and other inflamed skin.
The interest behind that is real but narrow. In mice given colitis chemically, and in colon cells in a dish, it quietens inflammatory signaling. The FDA states it has found no data on any person receiving it, by any route.
No completed controlled human trial has shown which dose works for KPV. There is no study-backed human dosing program to publish. Animal quantities are not converted into a human recommendation.
no human dose shown to work
Each row uses 10 mg and the liquid volume shown. Dividing the amount by that volume gives the calculated concentration. The rows are arithmetic examples, not alternative product preparations.
With 2 mL bacteriostatic water
10.0 units
With 3 mL bacteriostatic water
15.0 units
| Bacteriostatic water | Concentration | Per U-100 unit | Draw for 500 mcg | Nearest syringe line |
|---|---|---|---|---|
| 2 mL | 5.00 mg/mL | 50.0 mcg | 10.0 u · 0.100 mL | exactly 10 u |
| 3 mL | 3.33 mg/mL | 33.3 mcg | 15.0 u · 0.150 mL | 16 u · 6.7% off |
The amount, liquid volume and dose shown here are the calculator’s starting example for KPV. Replace them with your own values. Every result in the table is calculated from those inputs.
The KPV guide does not identify an established human dose. Its evidence discussion and the calculator’s starting example serve different purposes. A volume that is straightforward to display is not evidence that the entered amount works.
The guide discusses preclinical work, including gut-cell and mouse research. Those studies address their own experimental questions. They do not establish an amount, preparation or schedule for a person.
A statement about missing human exposure data also needs its source and scope. It should not be expanded into a claim that nobody has ever received KPV. The calculator makes no such determination; its arithmetic does not count as human evidence.
The calculation starts from the vial amount entered. It cannot identify the contents, test purity or measure strength. A familiar name or the appearance of a preparation cannot supply those missing measurements.
This limitation does not depend on assumptions about who supplied a vial or what it cost. The arithmetic is conditional on the inputs. If they do not describe the preparation accurately, the displayed concentration and draw will not describe it accurately either.
The KPV presets include different vial strengths. At the same liquid volume, the stronger vial requires a smaller draw for the same amount. The same number of syringe units would therefore represent different amounts across those setups.
The starting examples can be displayed within the barrel, but that does not establish safety or make rounding irrelevant. The output reports the current target and marked reading. It does not select an amount or a treatment schedule from how easy the scale looks.
The cited FDA review and laboratory papers do not provide a supported human dose for the tool. The material reviewed includes topical preparations and preclinical experiments. Those contexts do not establish a schedule for an injected vial.
Cell experiments state how much KPV was in the liquid around the cells. That is not an amount given to a person. To translate it, we would need to know how it enters, spreads through and leaves the body. Vial volume does not answer those questions.
The tool can explain the concentration produced by the mass and water entered. Its example does not fill the evidence gap or establish an injection route. The FDA assessment found no human exposure data to answer those questions.
Cell experiments state how much KPV was in the liquid around the cells. That is not an amount given to a person. To translate it, we would need to know how it enters, spreads through and leaves the body. Vial volume does not answer those questions.
The tool can explain the concentration produced by the mass and water entered. Its example does not fill the evidence gap or establish an injection route. The FDA assessment found no human exposure data to answer those questions.
Mix 10 mg into 3 mL and one U-100 unit carries 33.3 mcg. The table shows how much peptide is in each numbered syringe line. These are conversion examples, not suggested doses.
| U-100 line | Volume | Mass (mcg) | Mass (mg) |
|---|---|---|---|
| 10 u | 0.10 mL | 333 mcg | 0.333 mg |
| 20 u | 0.20 mL | 667 mcg | 0.667 mg |
| 30 u | 0.30 mL | 1,000 mcg | 1 mg |
| 40 u | 0.40 mL | 1,333 mcg | 1.333 mg |
| 50 u | 0.50 mL | 1,667 mcg | 1.667 mg |
| 60 u | 0.60 mL | 2,000 mcg | 2 mg |
| 70 u | 0.70 mL | 2,333 mcg | 2.333 mg |
| 80 u | 0.80 mL | 2,667 mcg | 2.667 mg |
| 90 u | 0.90 mL | 3,000 mcg | 3 mg |
| 100 u | 1.00 mL | 3,333 mcg | 3.333 mg |
The math is only one part of the question. These guides cover the compound, published doses, side effects, mixing steps and supplies.